InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 794,600 shares, an increase of 36.8% from the March 15th total of 581,000 shares. Based on an average daily volume of 391,800 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IFRX. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of InflaRx in a research note on Friday, March 21st. Guggenheim lifted their target price on shares of InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th.

Institutional Investors Weigh In On InflaRx

Several institutional investors have recently modified their holdings of the company. Two Sigma Securities LLC purchased a new stake in shares of InflaRx during the 4th quarter worth $28,000. Geode Capital Management LLC lifted its position in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after purchasing an additional 11,900 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock worth $275,000 after purchasing an additional 19,000 shares during the last quarter. Walleye Capital LLC purchased a new stake in InflaRx in the fourth quarter valued at $51,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in InflaRx in the fourth quarter valued at $55,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Stock Performance

Shares of IFRX stock traded up $0.06 on Thursday, hitting $1.26. 78,543 shares of the stock traded hands, compared to its average volume of 224,255. The firm's 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.82. The stock has a market capitalization of $84.25 million, a PE ratio of -1.16 and a beta of 2.21. InflaRx has a twelve month low of $0.82 and a twelve month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, equities research analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.